Document is current
Any future updates will be listed below
-
Authors
Theobald, Vivienne
Schmitt, Felix Carl Fabian
Middel, Chiara Simone
Gaissmaier, Lena
Brenner, Thorsten
Weigand, Markus Alexander
-
Funding
Funding for this research was provided by:
Medizinische Fakultät Heidelberg der Universität Heidelberg
- License Information
-
More Information
Article History
Received: 1 November 2023
Accepted: 4 January 2024
First Online: 9 January 2024
Declarations
:
: Not applicable.
: Not applicable.
: VT, FSCS, CSM and LG have no conflicts of interest. MW received grants from Köhler Chemie, DFG and BMBF, consulting fees from B. Braun, Gilead, Mundipharma and Boehringer Ingelheim, and payment or honoraria for lectures, presentations, or educational events from MSD, Gilead, Shionogi, Pfizer and Beckman Coulter. Dr Weigand is also a patent owner (EP17185036.5 and EP17198330.7), has participated on advisory boards for MSD, Gilead, Shionogi, Biotest, Pfizer, Eumedica, SOBI and Beckman Coulter, is the vice-head of the German Sepsis Society and member of the scientific advisory council of PEG, and is cofounder of Delta Theragnostics. TB received scientific grants from Deutsche Forschungsgemeinschaft (DFG), Innovation Fund of the Federal Joint Committee (G-BA), Dietmar Hopp Stiftung, Heidelberg Foundation of Surgery as well as Stiftung Universitätsmedizin Essen. Moreover, he received honoraria for lectures as well as advisory board participation from Baxter Deutschland GmbH, Schöchl medical education GmbH, Boehringer Ingelheim Pharma GmbH, CSL Behring GmbH, Astellas Pharma GmbH, B. Braun Melsungen AG, MSD Sharp & Dohme GmbH, BRAHMS GmbH, Lücke Kongresse GmbH, Georg Thieme Verlag GmbH as well as Akademie für Infektionsmedizin e.V.
